Friday, August 22, 2008

FDA Approves Nplate(TM) for Long-Term Treatment of Adult Chronic ITP

First and Only Approved Platelet Producer Represents New Treatment Approach for Serious Chronic Autoimmune Disorder Amgen to Launch Nplate(TM) NEXUS Program to Provide Treatment Access and Patient Support Programs

THOUSAND OAKS, Calif. –Aug 22, 2008 – Amgen Inc. (NASDAQ: AMGN) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nplate(TM) (romiplostim), the first and only platelet producer for the treatment of thrombocytopenia in splenectomized (spleen removed) and non-splenectomized adults with chronic immune thrombocytopenic purpura (ITP). Nplate, the first FDA-approved peptibody protein, works by raising and sustaining platelet counts, representing a novel approach for the long-term treatment of this chronic disease.

Posted in Press Releases, Product News